Human Genome Sciences Inc

Human Genome Sciences — Corporate Update (April 2012)

15 slides from Human Genome Sciences's corporate update, Apr 24, 2012

  1. Slide 1: Conference Call & Webcast April 24, 2012

    CONFERENCE CALL & WEBCAST April 24, 2012

  2. Slide 2: Note Regarding Forward-Looking Statements

    2 NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include those regarding our expectations for BENLYSTA(r), darapladib, and other asse

  3. Slide 3: Executive Summary

    We remain confident in the future potential of HGS and our Board is committed to maximizing shareholder value BENLYSTA - a blockbuster in progress BENLYSTA is the first drug in >50 years to be approved for the treatment of Lupus Lupus is a complicated disease with a unique treatment approach - physi

  4. Slide 4: BENLYSTA: The First Drug in 50 Years to Treat Lupus

    Clinical and Regulatory Success: The only treatment to complete randomized placebo-controlled Phase 3 trials successfully in patients with SLE A broad label reflecting success in the clinic1 Strong Market Demand: 90%+ intent-to-use BENLYSTA among rheumatologists Estimated initial U.S. market of ~200

  5. Slide 5: SLE Is a Unique and Complicated Disease, Which Impacts the Rate of New Treatment Adoption

    SLE IS A UNIQUE AND COMPLICATED DISEASE, WHICH IMPACTS THE RATE OF NEW TREATMENT ADOPTION 5 A chronic, life-threatening autoimmune disease, complicated by the following: Often affects multiple organ systems simultaneously (skin, joint and immunologic most common) Broad set of symptoms, including sev

  6. Slide 6: Adoption by Physicians Is Accelerating

    6 ADOPTION BY PHYSICIANS IS ACCELERATING Waiters ...with Increasing Rate of Adoption in 1Q12 vs. 4Q11 Physicians try BENLYSTA on select patients, then observe clinical outcomes before adopting more broadly Accounts with > $15k Rolling 4-Week Average (~5+ patients) Physicians are Increasingly Trying

  7. Slide 7: In Market Research, Physicians Perceive Patients Are Experiencing Benefit

    IN MARKET RESEARCH, PHYSICIANS PERCEIVE PATIENTS ARE EXPERIENCING BENEFIT1 Manifestations of SLE Symptoms Triggering BENLYSTA Prescription ~ % of Patients Fatigue 86% Arthritis 83% Rash 62% Anti-dsDNA Positive 61% Inability to Taper Steroids 56% Low Complement Level 42% Hematologic 39% Serositis 37%

  8. Slide 8: BENLYSTA Is a Blockbuster in Progress

    Moderate 45% Severe 22% Initial Target: 200,000 Patients Over the Course of Their Disease2,3 Estimated 1,500,000 Patients with Lupus and Related Conditions in the U.S.1 325,000 SLE Patients Treated by Rheumatologists2 8 1 Per Lupus Foundation of America 2 Per HGS primary market research 3 Within BEN

  9. Slide 9: Pipeline Provides Upside Opportunity for Our Shareholders

    PIPELINE PROVIDES UPSIDE OPPORTUNITY FOR OUR SHAREHOLDERS 9 Raxibacumab Inhalation Anthrax3 BENLYSTA(r) Systemic Lupus1, 2 Type 2 Diabetes Albiglutide Darapladib Cardiovascular Disease Marketed BENLYSTA Vasculitis4 BENLYSTA Active Lupus Nephritis4 Alzheimer's Disease Rilapladib

  10. Slide 10: Darapladib: First in Class Lp-PLA2 Inhibitor

    First in class small molecule inhibitor of Lp-PLA2, an enzyme associated with formation of atherosclerotic plaques Target implicated in the inflammatory component of plaque formation Large epidemiological trials have identified Lp-PLA2 as an independent risk factor (from LDL cholesterol) for coronar

  11. Slide 11: Darapladib - A Multi-Billion Dollar Product Opportunity

    2011 WW Branded Statins and Plavix Markets ($ in billions) Addressable Patient Population (millions) DARAPLADIB - A MULTI-BILLION DOLLAR PRODUCT OPPORTUNITY 11 If approved, darapladib would provide a new option for reducing the risk of adverse CV events Significant market opportunity across a range

  12. Slide 12: Other Pipeline Opportunities - Balanced Portfolio of Partnered and Wholly Owned Product Candidates

    OTHER PIPELINE OPPORTUNITIES - BALANCED PORTFOLIO OF PARTNERED AND WHOLLY OWNED PRODUCT CANDIDATES 12 Raxibacumab for inhalation anthrax Monoclonal antibody generating revenue under U.S. government contract Albiglutide for Type 2 diabetes (T2D) Once weekly GLP-1 agonist discovered by HGS and license

  13. Slide 13: Notable Operational and Financial Assets

    Significant NOL value $2.4 billion in net operating losses (NOLs) are a valuable tax asset Strong balance sheet Cash on hand of $799 million provides capital base for continued BENLYSTA launch, pipeline execution and near-term debt maturity $207 million 2.25% Convertible Notes due August 2012 $495 m

  14. Slide 14: No Adverse Change-of-Control Provisions Tied to GSK Partnership

    NO ADVERSE CHANGE-OF-CONTROL PROVISIONS TIED TO GSK PARTNERSHIP 14 In change of control, all of HGS' rights flow to acquiror Full transferability of BENLYSTA, darapladib, albiglutide and rilapladib rights and economics to a third party acquiror No loss of economic or operational control relative to

  15. Slide 15: Summary of HGS Value Proposition

    We remain confident in the future potential of HGS and our Board is committed to maximizing shareholder value BENLYSTA - a blockbuster in progress Darapladib - a blockbuster in the making Upon a change of control, our financial and commercial rights to all programs are fully transferable Pipeline re

Human Genome Sciences — Corporate Update (April 2012) on 6ix